Mebendazole restores gefitinib activity by inducing DNA damage in resistant lung cancer cells
Mebendazole combined with gefitinib increased DNA damage and suppressed growth in preclinical models of gefitinib-resistant non-small cell lung cancer.
Nathaniel Bowman is a Scienmag editorial specialist profile for Precision Oncology coverage.
Mebendazole combined with gefitinib increased DNA damage and suppressed growth in preclinical models of gefitinib-resistant non-small cell lung cancer.
A retrospective study of 38 patients with advanced HPV16-positive cancers linked baseline and early serum protein measurements to outcomes from...
MSIPep combines immunopeptidomics, transcriptomics and deep learning to identify and computationally prioritize candidate tumor peptides in leukemia and solid-tumor datasets.
A retrospective analysis of 154 patients with unresectable hepatocellular carcinoma found that low baseline handgrip strength was associated with shorter...
A prospective study of 205 colorectal cancer surgery patients found that an XGBoost model using four clinical variables predicted six-month...
A review finds that three-dimensional cultures and organ-on-a-chip devices reveal context-dependent neutrophil behavior and provide preclinical platforms for testing neutrophil-based...
A critical review finds that PRKAR2A is a plausible spatial regulator of cAMP–PKA signalling in triple-negative breast cancer, although current...
A peer-reviewed review examines protein acylation as a link among cancer metabolism, tumor plasticity, therapeutic resistance and proposed biomarker-guided treatment...
A FAERS analysis of 786 ifosfamide-related neurological reports found a strong encephalopathy signal, a median onset of two days and...
A retrospective nationwide cohort of 301 patients found a 10.6% incidence of adverse events after malignant vena cava stenting, with...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine